Latest Pharmacy biotechnology articles and news on biotech industry leaders, emerging biotech companies in Spain

IBRILATAZAR (ABTL0812) from AbilityPharma increases chemotherapy effectiveness by 40% in patients with endometrial cancer

by AbilityPharma

2 years ago
ibrilatazar (ABTL0812), PI3K, endometrial cancer

The trial evaluated the safety and efficacy of ibrilatazar (ABTL0812) combined with paclitaxel/carboplatin in 51 patients with advanced or recurrent endometrial cancer, across 9 leading oncology hospi...

ORYZON announces first patient dosed in an Investigator-initiated Phase Ib study of iadademstat in first-line acute myeloid leukemia

by Oryzon Genomics

2 years ago
iadademstat, acute myeloid leukemia (AML), azacitidina+venetoclax, gilteritinib

Exploring the triple combination with venetoclax and azacitidine

Una validación que aporta excelencia a Mikrobiomik y a la industria farmacéutica

by Mikrobiomik Healthcare Company

2 years ago
MBK-01, QUANTOM TXTM

Se ha introducir el equipo QUANTOM TxTM un contador de células microbianas y validar el método de recuento de microorganismos totales como control de calidad dentro del proceso productivo del medica...

ORYZON receives 'Intention to grant' communication for patent relating to the use of vafidemstat in Borderline Personality Disorder

by Oryzon Genomics

2 years ago
vafidemstat, Oryzon, European patent

Oryzon Genomics announced today that the European Patent Office (EPO) has issued an “intention to grant” communication for Oryzon’s European patent application EP20712565.9 entitled “Methods o...

Biotechnology, at the forefront of the fight against sepsis, one of the world's most serious and deadly conditions, with a 20% mortality rate

by Asebio

2 years ago
NLRP3 Inflammasome Activation, Ex Vivo Monocytes, sepsis, “BIAlert Sepsis

The use of artificial intelligence or an innovative approach focused on measuring NLRP3 inflammasome activation in monocytes ex vivo are examples of the latest advancements against sepsis.

Engrail Therapeutics Initiates ENX-104 Clinical Program for the Treatment of Major Depressive Disorder Characterized by Anhedonia

by Ysios Capital

2 years ago
ENX-104, anhedonia (aMDD), Engrail Therapeutics

The first-in-human Phase 1 clinical study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic profile of ENX-104 in healthy volunteers

A new computational tool identifies more than 32,000 points of pharmacological interest in the human proteome

by IRB Barcelona - Instituto de Investigación Biomédica

2 years ago
PocketVec

Scientists at IRB Barcelona develop PocketVec, an innovative method to detect and characterise pharmacologically targetable sites in human proteins.

ORYZON presents the final data from PORTICO, a global Phase IIb vafidemstat trial in Borderline Personality Disorder (BPD), at the European College of Neuropsycopharmacology (ECNP) congress

by Oryzon Genomics

Oryzon announced that it will present today the final data from its Phase IIb PORTICO trial of vafidemstat in patients with Borderline Personality Disorder (BPD) as an oral presentation at the New Med...

Farmacoterapia y ejercicio, aliados necesarios para tratar la obesidad

by Universidad Politécnica de Madrid

2 years ago
agonistas del receptor de GLP-1 y GIP + ejercicio físico, obesidad

Un estudio de la Universidad Politécnica de Madrid y de la Universidad de Granada encuentra evidencias de los beneficios de la combinación del ejercicio físico con el tratamiento de farmacoterapia ...

3PBIOVIAN recibe el premio Talent Acceleration en los BWB Awards 2024 en Boston

by 3PBIOVIAN

2 years ago
3PBIOVIAN, BWB Awards

La compañía navarra es reconocida por su enfoque innovador en la formación y desarrollo de talento en el sector biofarmacéutico

Una bioimpresora para la producción de piel humana.

by Peaches Biotech

2 years ago
bioimpresión, 4D-BIOSKIN, queratinocitos y fibroblastos

Este proyecto de medicina personalizada y regenerativa llevará a cabo el primer ensayo clínico en España para tratar quemaduras y heridas cutáneas con sustitutos autólogos de piel humana bioimpre...

Lecanemab y los inicios de una nueva era en el tratamiento del Alzheimer

by Fundación Pasqual Maragall

2 years ago
lecanemab, Alzheimer, donanemab

En enero de 2023 el fármaco recibió la autorización del organismo regulador americano de alimentos y medicamentos, la Food and Drug Administration (FDA), por la vía de aprobación acelerada y, a p...